505 related articles for article (PubMed ID: 26280447)
81. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
82. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
83. Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
Krittanawong C; Kitai T
Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28489317
[TBL] [Abstract][Full Text] [Related]
84. Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option.
Bramblett T; Teleb M; Albaghdadi A; Agrawal H; Mukherjee D
Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):80-85. PubMed ID: 28676030
[TBL] [Abstract][Full Text] [Related]
85. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
[TBL] [Abstract][Full Text] [Related]
86. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
[TBL] [Abstract][Full Text] [Related]
87. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
Hsiao R; Greenberg B
Curr Heart Fail Rep; 2016 Aug; 13(4):172-80. PubMed ID: 27271564
[TBL] [Abstract][Full Text] [Related]
88. Entresto, a New Panacea for Heart Failure?
Khalil P; Kabbach G; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):5-11. PubMed ID: 29532764
[TBL] [Abstract][Full Text] [Related]
89. Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
Lu BN; Davis LE
JAAPA; 2018 Jul; 31(7):35-37. PubMed ID: 29957605
[TBL] [Abstract][Full Text] [Related]
90. New medications for heart failure.
Gordin JS; Fonarow GC
Trends Cardiovasc Med; 2016 Aug; 26(6):485-92. PubMed ID: 27038558
[TBL] [Abstract][Full Text] [Related]
91. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
[TBL] [Abstract][Full Text] [Related]
92. Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.
Segura J; Salazar J; Ruilope LM
Expert Opin Investig Drugs; 2013 Jul; 22(7):915-25. PubMed ID: 23731190
[TBL] [Abstract][Full Text] [Related]
93. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Braunwald E
J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
[TBL] [Abstract][Full Text] [Related]
94. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
[TBL] [Abstract][Full Text] [Related]
95. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Ayalasomayajula S; Langenickel T; Pal P; Boggarapu S; Sunkara G
Clin Pharmacokinet; 2017 Dec; 56(12):1461-1478. PubMed ID: 28417439
[TBL] [Abstract][Full Text] [Related]
96. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
[TBL] [Abstract][Full Text] [Related]
97. Efficacy of Sacubitril/Valsartan in Hypertension.
Malik AH; Aronow WS
Am J Ther; 2022 May-Jun 01; 29(3):e322-e333. PubMed ID: 30664018
[TBL] [Abstract][Full Text] [Related]
98. Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
Gulin D; Planinic Z; Habek JC; Sikic J
Indian J Pharmacol; 2019; 51(6):413-415. PubMed ID: 32029965
[TBL] [Abstract][Full Text] [Related]
99. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.
Wehland M; Simonsen U; Buus NH; Krüger M; Grimm D
Expert Opin Pharmacother; 2020 Jul; 21(10):1133-1143. PubMed ID: 32133873
[TBL] [Abstract][Full Text] [Related]
100. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
Pham AQ; Patel Y; Gallagher B
J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
